Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates whether chronic heart rate reduction with ivabradine (Procoralan®, Servier, France) affects aortic compliance and endothelial function in patients with chronic stable coronary artery disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Saarland
• Collaborators: Saarland University; Universität des Saarlandes

Criteria

Inclusion Criteria:

• Age > 18 years old

• Resting heart rate ≥ 70 bpm

• Sinus rhythm

• Chronic stable coronary artery disease (CAD)

• Coronary artery disease proven by coronary angiography

• Written informed consent to participate in the study

Exclusion Criteria:

• Acute coronary syndrome

• CAD treated best by surgical coronary bypass

• Stroke/TIA

• Resting heart rate < 70 bpm

• Indwelling pacemaker or AICD

• Severe valvular heart disease

• Any other rhythm than sinus

• Sick-Sinus-Syndrome, SA nodal block, >2nd degree atrio-ventricular block

• Untreated arterial hypertension

• Arterial hypotension (<90/50mmHg)

• Severe hepatic failure

• Heart failure (NYHA class III - IV)

• Patient already treated with study drug

• Symptomatic PAD

• Known diabetes mellitus

• Pre-menopausal women

• Hypersensitivity against ivabradine or adjuvants

• Coexisting drug treatment with Cytochrom P450 3A4-inhibitors